Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.18 -4.8%	$1.36	$1.05 ▼ $10.16	$37M	1.55	254,280 shs	251,221 shs
MBRX Moleculin Biotech	$0.27 -54.2%	$0.88	$0.25 ▼ $4.71	$3.77M	1.56	1.62 million shs	16.49 million shs
PDSB PDS Biotechnology	$1.62 +0.6%	$1.41	$0.85 ▼ $4.42	$74.05M	1.27	495,529 shs	898,647 shs
SKYE Skye Bioscience	$2.16 +0.9%	$2.14	$1.14 ▼ $8.44	$66.91M	1.69	362,237 shs	290,100 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	0.00%	-1.67%	+2.61%	-77.99%	-82.20%
MBRX Moleculin Biotech	0.00%	-58.41%	-71.59%	-75.50%	-93.29%
PDSB PDS Biotechnology	0.00%	-7.43%	+3.18%	+18.25%	-40.88%
SKYE Skye Bioscience	0.00%	+5.11%	+4.10%	-4.64%	-77.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	3.8214 of 5 stars	4.5	5.0	0.6	3.3	0.6
MBRX Moleculin Biotech	3.1452 of 5 stars	3.5	5.0	2.6	0.0	1.3
PDSB PDS Biotechnology	1.3216 of 5 stars	3.7	1.0	2.0	0.0	0.0
SKYE Skye Bioscience	2.0224 of 5 stars	3.5	2.0	2.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,401.21% Upside
MBRX Moleculin Biotech	3.00	Buy	$4.00	1,398.13% Upside
PDSB PDS Biotechnology	3.33	Buy	$9.00	455.56% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	668.52% Upside

Current Analyst Ratings Breakdown

Latest MBRX, PDSB, ACRV, and SKYE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/11/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/27/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $13.00
3/26/2025	ACRV Acrivon Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/26/2025	ACRV Acrivon Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$1.77 per share	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.51 per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.22	N/A	N/A	N/A	N/A	-44.66%	-40.94%	8/12/2025 (Estimated)
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-278.80%	-100.11%	8/4/2025 (Estimated)
PDSB PDS Biotechnology	-$37.61M	-$0.94	N/A	N/A	N/A	N/A	-150.59%	-69.15%	8/12/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$0.82	N/A	N/A	N/A	N/A	-53.92%	-48.58%	N/A

Latest MBRX, PDSB, ACRV, and SKYE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	PDSB PDS Biotechnology	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A
3/27/2025	Q4 2024	PDSB PDS Biotechnology	-$0.29	-$0.21	+$0.08	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	11.17	11.17
MBRX Moleculin Biotech	N/A	1.35	1.35
PDSB PDS Biotechnology	0.29	2.33	2.33
SKYE Skye Bioscience	N/A	11.85	11.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
MBRX Moleculin Biotech	15.52%
PDSB PDS Biotechnology	26.84%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
MBRX Moleculin Biotech	1.90%
PDSB PDS Biotechnology	9.20%
SKYE Skye Bioscience	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.35 million	27.62 million	Not Optionable
MBRX Moleculin Biotech	20	14.13 million	13.86 million	Not Optionable
PDSB PDS Biotechnology	20	45.71 million	41.51 million	Optionable
SKYE Skye Bioscience	11	30.98 million	29.58 million	Optionable

MBRX, PDSB, ACRV, and SKYE Headlines

Recent News About These Companies

Skye Bioscience (NASDAQ:SKYE) Trading 23.1% Higher - Should You Buy?

June 20 at 3:15 AM | marketbeat.com

Skye confirms phase 2 data on nimacimab for obesity expected later this year

June 19 at 10:46 AM | msn.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

June 17, 2025 | finance.yahoo.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

June 17, 2025 | globenewswire.com

Cantor Fitzgerald Weighs in on Skye Bioscience FY2026 Earnings

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Predicts Skye Bioscience FY2026 Earnings

June 10, 2025 | marketbeat.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Buy" from Analysts

June 8, 2025 | marketbeat.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Brokerages

June 8, 2025 | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Trading Up 24% - Here's What Happened

May 31, 2025 | marketbeat.com

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

May 23, 2025 | zacks.com

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025 | globenewswire.com

Skye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity Treatment

May 21, 2025 | nasdaq.com

Q&A: Next wave of obesity drugs may ‘afford a lot of advantages’

May 20, 2025 | healio.com

Arecor shares climb 18% on collaboration with Skye Bioscience

May 19, 2025 | lse.co.uk

Arecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate Nimacimab

May 19, 2025 | cambridgenetwork.co.uk

Skye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025 | finanznachrichten.de

Arecor enters formulation partnership with Skye Bioscience

May 19, 2025 | sharecast.com

Arecor shares jump 10% on obesity drug partnership with Skye Bioscience

May 19, 2025 | proactiveinvestors.co.uk

Arecor partners with Skye Bioscience to improve formulation of obesity drug

May 19, 2025 | proactiveinvestors.co.uk

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025 | globenewswire.com

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, PDSB, ACRV, and SKYE Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.18 -0.06 (-4.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.22 +0.04 (+3.39%)

As of 06/20/2025 07:56 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Moleculin Biotech NASDAQ:MBRX

$0.27 -0.32 (-54.20%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.26 0.00 (-1.12%)

As of 06/20/2025 07:57 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

PDS Biotechnology NASDAQ:PDSB

$1.62 +0.01 (+0.62%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.65 +0.03 (+1.79%)

As of 06/20/2025 07:57 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Skye Bioscience NASDAQ:SKYE

$2.16 +0.02 (+0.93%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.16 0.00 (0.00%)

As of 06/20/2025 06:59 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time